Hansoh Pharmaceutical (03692) Announces NMPA Approval of the Fifth Indication for Ameile® (Almonertinib Mesilate Tablets)

Hansoh Pharma(03692) announced that the group's innovative drug, Amelie® (Aumolertinib Mesylate Tablets), has received a drug registration certificate issued by the National Medical Products Administration ("NMPA") of China. The approval adds a new indication: "Amelie® in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") harboring epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21(L858R) substitution mutations." This is the fifth approved indication for Amelie®.